Vor Biopharma Inc Cash Flow Conversion Efficiency
Vor Biopharma Inc cash flow conversion efficiency. Based on the latest financial reports, Vor Biopharma Inc (VOR) has a cash flow conversion efficiency ratio of 0.128x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-25.67 Million) by net assets ($-200.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vor Biopharma Inc (2018–2025)
Cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2025. This chart illustrates how Vor Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Vor Biopharma Inc for real-time trading data and today's change.
Vor Biopharma Inc Cash Flow Conversion Ratio Explained
Vor Biopharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vor Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vor Biopharma Inc ranked by their cash flow conversion efficiency. Also see Vor Biopharma Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
0.072x |
|
China Security & Fire Co Ltd Class A
SHG:600654
|
-0.009x |
|
HeBei Jinniu Chemical Industry Co Ltd
SHG:600722
|
0.017x |
|
Under Armour Inc C
NYSE:UA
|
0.076x |
|
Mahanagar Gas Limited
NSE:MGL
|
0.083x |
|
Aevis Victoria SA
SW:AEVS
|
0.037x |
|
Willdan Group Inc
NASDAQ:WLDN
|
0.125x |
|
Actions Technology Co Ltd
SHG:688049
|
0.043x |
Annual Cash Flow Conversion Efficiency for Vor Biopharma Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vor Biopharma Inc from 2018 to 2025. Review how financially flexible is Vor Biopharma Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-164.31 Million | $-142.71 Million | 0.869x | +184.24% |
| 2024-12-31 | $96.66 Million | $-99.66 Million | -1.031x | -54.94% |
| 2023-12-31 | $150.72 Million | $-100.29 Million | -0.665x | -95.85% |
| 2022-12-31 | $250.61 Million | $-85.14 Million | -0.340x | -6.26% |
| 2021-12-31 | $216.26 Million | $-69.14 Million | -0.320x | +57.47% |
| 2020-12-31 | $48.27 Million | $-36.29 Million | -0.752x | +41.71% |
| 2019-12-31 | $7.64 Million | $-9.86 Million | -1.290x | -428.03% |
| 2018-12-31 | $-6.77 Million | $-2.66 Million | 0.393x | -- |
About Vor Biopharma Inc
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with Re… Read more